Yersinia pestis infection future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Changes made per Mahshid's request)
 
Line 21: Line 21:


[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Infectious disease]]
 
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Disease]]
[[Category:Disease]]

Latest revision as of 19:31, 18 September 2017

Yersinia pestis infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Yersinia Pestis Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Yersinia pestis infection future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Yersinia pestis infection future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Yersinia pestis infection future or investigational therapies

CDC on Yersinia pestis infection future or investigational therapies

Yersinia pestis infection future or investigational therapies in the news

Blogs on Yersinia pestis infection future or investigational therapies

Directions to Hospitals Treating Yersinia pestis infection

Risk calculators and risk factors for Yersinia pestis infection future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Current research aims to develop new and less invasive vaccines that protect from airborne infection of Yersinia pestis.

Future and Investigational Therapies

Research studies are under way to improve the plague vaccine. The qualities searched in the new vaccine include:[1]

  • Protection from airborne infection
  • Inhaled administration

A current potential vaccine is a recombinant type, expressing both V and F1 antigens of Yersinia pestis. This vaccine appears to protect animals against airborne infection with Yersinia pestis. Other options include:[1]

References

  1. 1.0 1.1 Mandell, Gerald (2010). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0443068399.

Template:WikiDoc Sources